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Abstract
This study reviewed the use of the Strengths and Weaknesses of Attention-Deficit/Hyperactivity-symptoms and Normal-
behaviors (SWAN) rating scale in diagnostic and evolutive approaches to attention deficit hyperactivity disorder (ADHD) and in
correlational studies of the disorder. A review of articles published in indexed journals from electronic databases was conducted
and 61 articles on the SWAN scale were analyzed. From these, 27 were selected to a) examine use of SWAN in research on
attention disorders and b) verify evidence of its usefulness in the areas of genetics, neuropsychology, diagnostics, psychiatric
comorbidities, neuroimaging, pharmacotherapy, and to examine its statistical reliability and validity in studies of diverse
populations. This review of articles indicated a growing use of the SWAN scale for diagnostic purposes, for therapy, and in
research on areas other than ADHD, especially when compared with other reliable scales. Use of the scale in ADHD diagnosis
requires further statistical testing to define its psychometric properties.
Key words: SWAN rating scale; Behavioral scale; Attention; Attention deficit hyperactivity disorder; Neuropsychology;
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Introduction
Attention deficit hyperactivity disorder (ADHD) affects
5-6% of the child and adolescent (age 6 to 12 years)
population (1). Its symptoms include excessive attention
deficit, hyperactivity, and impulsiveness, all of which
cause considerable social, emotional, and academic
problems. Such symptoms cause difficulties with school
education and emotional behavior, and lead to impaired
peer relationships. This is because individuals with ADHD
are easily distracted during conversations, experience
severe difficulty engaging in efficient and sustained
activity, and show deficits in inhibitory control (2). In 50%
of cases, these difficulties may persist into adulthood (3)
and have a significant impact on family and professional
life. For example, individuals with ADHD may experience
less profitable work opportunities, poorer academic
development, more accidents, family problems, mood
swings, and higher health care expenses compared with
non-affected persons (4).
Currently, the heritable genetic, clinical, and physiolog-
ical profiles of ADHD have been increasingly defined by
standards and references based on scientific, statistical,
and neuroimaging studies, as research has focused on
the search for endophenotypes and markers that can
further delineate physiopathological and diagnostic methods
(5–7). The growing use of multi-applicable assessment
questionnaires (those that can be administered by parents,
caregivers, teachers, or self-administered), and the devel-
opment of behavioral scales, have redimensioned and
facilitated ADHD evaluation. This has helped to achieve a
more standardized and accurate level of assessment, and
informed the interdisciplinary approaches to evaluation that
are necessary to ADHD diagnostics (8). According to
Waschbusch and Sparkes (9), rating scales are essential
subsidiary instruments in the investigation of ADHD for
various reasons: a) they are low-cost and easy to use in
the average clinic; b) they can be applied by different
people with different perspectives; for example, parents,
teachers, and caregivers; c) they can be used both in
diagnostic treatment and as research instruments, and d)
they provide the statistical reliability necessary to obtain a
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cut-off threshold for the diagnosis of behavioral disorders
and disorders without specific biological markers, such
as ADHD.
There are existing scales that have already been
standardized and validated to evaluate ADHD in children
and adolescents (10–12), for example: Conners (3rd
edn.); Conners Comprehensive Behavior Rating Scales;
Conners Early Childhood; the Vanderbilt ADHD Diagnos-
tic Parent/Teacher Rating Scales; ADHD Rating Scale-IV,
Swanson, Nolan, Pelham-IV Teacher and Parent Rating
Scale (SNAP-IV) ADHD Symptom Checklist-4; ADHD
Comprehensive Teacher Rating Scale; Brown Attention
Deficit Disorder Scales, Behavior Assessment System for
Children (2nd edn.); and Achenbach System of Empiri-
cally Based Assessment (8). These scales are based on
categorical assessment; that is, they focus on psycho-
pathology and extreme ADHD symptoms, which could
lead to evaluation errors that result in over-diagnosis or,
conversely, the failure to identify individuals with mild
ADHD symptoms. Since the 1960s, there have been
increasing attempts to confront this concern and to
examine the problem of bias in categorical scales, with
attempts to develop reliable scales that are free from
problems such as cultural differences, biases in the
selection of reference groups, and lack of objectivity in
the definition and evaluation of ‘‘deficit’’ and ‘‘behavioral
disorder’’ (13). Among the various existing scales that
evaluate the symptoms and signs of ADHD, the Strengths
and Weaknesses of ADHD-symptoms and Normal-
behaviors (SWAN) rating scale is based on observations
of normal and abnormal distributions of attention skills in
diverse population samples. SWAN has been used in
research on diagnostic and therapeutic approaches to
ADHD in children and adolescents (14).
The purpose of this review was to locate citations
containing scientific evidence that the SWAN scale can be
used to describe symptoms, evaluate individuals in relation
to the normal distribution of behaviors, evaluate possible
treatment, and is applicable to genome-wide association
studies (GWAS) and neuropsychological studies on ADHD.
We conducted a literature review and classified 28 articles
into seven areas of interest: genetics, neuropsychology,
diagnostics, psychiatric comorbidities, neuroimaging, phar-
macotherapy, and statistical reliability and validity.
Status of rating scales: considerations of
categorical and dimensional approaches
It is possible for the format of a rating scale or
questionnaire to affect responses and produce results that
may not accurately reflect reality (15). Many of these scales
are categorical and designed to simply detect the presence
or absence of a specific problem, as they report only
psychopathological items based on the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
(16). Different cultures may vary in their tolerance to, and
evaluation of, disruptive or socially unacceptable behavior.
Consequently, the results and interpretation of scales may
not reflect reality. Categorical scales (those which present
items meant to reveal whether a specific psycho-
pathological behavior exists) are more likely to exclude
significant, though subtler, information (yielding a false
negative). The opposite is also possible: biasing the results
to reflect a psychopathological condition (resulting in a false
positive) and increasing estimates of the number of
individuals in the general population who are affected by
severe presentations of the disorder.
Van der Sluis et al. (17), in their examination of the
power of statistical analysis in GWAS, emphasize that the
utilization of items that prioritize extreme behavior clearly
differentiates index cases from case-control studies;
however, this provides scarce information on phenotype
variations that exist both in cases and controls. They
argue that categorical approaches (and the majority of
categorical diagnostic instruments) constantly neglect
symptomatic data containing strong allelic relations
and diminish the capacity to detect the genetic effects
of phenotype traces distributed among the general
population (17).
In observations and analyses of attention behaviors or
motor activity, as with any other behavioral problem in the
general population, responses are compared to the
normal distribution; on this continuum, ADHD is defined
as the lower extreme (9,15,16). Studies have shown,
therefore, the importance of utilizing dimensional profile
scales for ADHD. Dimensional discrimination from the
average (level zero) to the extremes – high (–1, –2, –3),
low (+1, +2, +3) – is a form of behavioral analysis that
aims to evaluate problems or behavioral disorders, while
minimizing as much as possible social-cultural and
statistical biases (16). This is especially relevant in cases
where discrepancies should be analyzed in detail; for
example, with clinical decisions, genetic studies, eva-
luation of responses, therapies, and in comparing twins
or other relatives of those affected by the disorder.
ADHD is a disorder that has been influenced by the
model of genetic analysis of complex traits – copy
number variations (CNVs) and single nucleotides –
where the distribution of candidate genes toward a
specific phenotype variation is in an irregular order,
randomized, cumulative in a family, and in which the
resulting clinical profile displays high variability. None-
theless, if evaluated with categorical scales, many
ADHD patients with only mild symptoms may pass
unnoticed and would not be detected in a basic clinical
assessment (18–20).
In this context, Swanson et al. (16,21) demonstrated the
consequences of applying a scale using truncated summary
scores based on normal population behavior patterns; they
subsequently developed a new rating scale that reflected
the behavior of a normally distributed population in an
attempt to overcome the frequent problems and biases
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apparent in many earlier scales. Using one of their earlier
scales (the Swanson, Nolan, and Pelham-IV [SNAP-IV]
scale) as a reference, Swanson et al. created a new
scale based on the gradual severity of existing symptoms
in a model population; the more flexible the variation of
behavioral signs, the lesser the risk of failing to detect or
over-diagnosing the disorder. They thus generated a
more accurate distributive profile of the scores, revising
the SNAP-IV scale, which was based on a categorical/
physiological model, to produce the SWAN scale based
on a model of the behavior/dimensions of the population.
In this scale, every item is presented using a grading
system that ranges from neutral to extremely positive or
negative; the observer or caregiver completing the
ratings is directed to compare the rated party’s behavior
with the average age and culture-specific behavior
expected (16,21). To accomplish this, the items on the
scale were rephrased to represent the full range of
behavior (rather than just categorical classification of
psychopathology), which could then be analyzed more
accurately in relation to norms.
SWAN Rating Scale
The SWAN scale was created by Swanson et al. (16)
and comprises 30 items measuring the full range of
behavior, instead of only the pathological signs and
symptoms of ADHD. The items measure behavioral
characteristics representative of the attention skills of the
general population. Raters are asked to evaluate the child/
adolescent by comparing them to other children of the
same age group, and from the same family and school
environment, on skills such as focusing attention, control-
ling anxiety, and inhibiting impulsive behavior during tasks
that require prolonged mental effort and during daily
activities. On the complete scale, each item is scored
from –3 to +3 (below average to above average), where 0
(zero) is normal and based upon the population average
(see Figure 1). These variations result in normally
distributed behavioral rates.
Electronic database search
This literature review searched electronic databases
for relevant international scientific journals, specialized
books, notes from academic debates, and notes from
research teams.
The following initial criteria were used: 1) articles
published from 2000 (when the development of the scale
first began and the first reports were issued) to 2014; 2)
digitally published studies in online databases (MEDLINE,
PubMed, SciELO, and BIREME); 3) notes from academic
debates and notes from research teams published in
newspapers and magazines.
The following keywords were used for the electronic
search: ADHD and SWAN scale, SWAN and genetics,
SWAN and neuroscience, and neuropsychological assess-
ment. A total of 61 scientific studies that mentioned SWAN in
ADHD research were analyzed from this period, out of which
27 were selected and meticulously assessed and analyzed
to determine the use of the scale in ADHD studies associated
with the following subjects: diagnostic approaches to ADHD
symptoms, genetic studies (between twins and siblings of
ADHD carriers), the evolution of medical interventions,
studies related to neuropsychological aspects of ADHD,
studies on the reliability and validity of statistics, neuroimag-
ing, and the interface between ADHD and neuropsychiatric
comorbidities. All of these articles are summarized in Table 1.
Literature review
The literature review was structured around seven
fields of ADHD research in which the SWAN scale was
used, and examined studies in the following areas:
diagnostic evaluation and symptoms, genetics, the evolu-
tion of therapeutics and pharmacotherapeutics, aspects of
neuropsychology, statistical reliability and validity, comor-
bidities, and neuroimaging.
Studies of ADHD diagnostic evaluation and
symptoms
Overall, the articles examined indicate that the scale
permits the analysis of attention skills in large normal
population samples because it provides – by its dimensional
profile – common signs of selective, sustained, and
executive attention in items that reflect normal behavior
observed in the general population. This aspect makes it
possible to compare control groups with groups showing
deviations from average scores on attentional items
disproportionate to a normal population. Three articles
showed that the distribution of these abilities in the
populations researched resembled a Gaussian curve (22),
a distribution often found in GWAS evaluations of behavior
and in studies of complex traits. Furthermore, using an
average standard deviation cut off of 1.65, the scale
identified an abnormal prevalence in 4% of the population;
this is compatible with international ADHD statistics, which
identify a prevalence of approximately 5% (15,16,23,24).
Therefore, ADHD – which is a disorder characterized by
greater abnormalities in attention levels than those found in
non-ADHD individuals – can be evaluated using this scale
with reduced risk of biases compared to the SNAP-IV
(16,21) and other scales (25–28). The SNAP-IV distribution
of scores in normal samples exhibits a very different graphic
profile: asymmetrical (hyperbolic) and skewed to the left
(16,21). The same pattern is found for Child Behavior
Checklist (CBCL) profile scores (25).
These articles also suggest that the SWAN scale can
detect negative signs and traces of ADHD in a population
when compared to previously published and validated
scales, such as the Disruptive Behavior Rating Scale
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(DBRS) and the ADS-IV (Assessment Disruptive Scale/
DSM-IV) (20) as it can help to define subtypes in studies
with twins (27) and of cohorts (20,29) because of its ability
to detect small phenotypic variations. Some studies show
that, compared with the CBCL-Attention Problem Scale,
Preschoolers with ADHD Treatment Study (PATS), and
DBRS, SWAN has been used to control over-identification
of extreme cases in diagnostics, to detect both positive and
negative ADHD symptoms, and to evaluate the therapeutic
response to stimulants and to behavioral physiotherapy
both in schools and communities (25,26,30), including the
evaluation of both English- and Spanish-speaking pre-
schoolers (28). In one study examining ADHD symptoms in
impulsive patients and those with executive dysfunctions,
the scale was sensitive in discriminating attention and
motor control symptoms (31).
Genetic studies
With regard to genetic ADHD studies, three articles
showed that the scale is an adequate instrument for
detecting phenotype traces of ADHD in the general
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population, and in helping to link these traces with mutations
and genotype segments distributed in samples from twins
and their siblings; for example, the dopamine transporter
(DAT) 10/10-repeat allele (32). In addition, SWAN has been
used in multicultural population studies searching for traces
of ADHD with genetic variants, such as the latrophilin 3
gene (33) and DAT1 (34). It is well known that ADHD is
predominately a genetic condition and the search for
endophenotypic markers related to candidate genes
requires analysis and crosschecking of complex data. This
process requires the adoption of dimensional scales, which
present the disorder as the extreme of a behavioral
continuum (17), to objectively establish the direct link
between symptoms and genes. This is reflected in studies
involving twins and their siblings, in which the SWAN
scale was more ‘‘realistic’’ in exhibiting a more complete
phenotype of ADHD in the distribution of symptoms in these
groups and in the correlation of symptoms with hereditary
genetics (27). In all of these articles, SWAN showed
significant reliability and validity when compared with other
behavioral rating scales.
Studies on the evolution of
pharmacotherapeutics
Two studies – Abikoff and Vitiello – used the SWAN
scale along with other valid scales to evaluate responses
in the functionality of children with ADHD who took the
central nervous system stimulant methylphenidate for
4 weeks (35) and 40 weeks (26). Behavioral variations
were observed in emotional status, social abilities,
classroom behavior, and in relation to parents. Using
Table 1. The 27 articles on SWAN selected for review, and the areas of attention deficit hyperactivity disorder (ADHD) research, their
authors, journals, and samples.
Year ADHD theme Authors References Sample
2000 Reliability/Validity Swanson et al. www.adhd.net/SWAN_
SCALE.pdf
847 child (SNAP) and 506 (SWAN)
2001 Reliability/Validity Swanson et al. www.adhd.net/SWAN_
SCALE.pdf
847 children
2003 Reliability/Validity Waschbusch & Sparkes J Psych Assess 826 males and 756 females
2005 Genetic Cornish et al. Mol Psych 872 boys
2006 Comorbidity Martin et al. Human Mov Sci 1285 participants (age 5–16)
2007 Neuropsychology Lui & Tannock Behav Brain Funct 120 children (age 7–12)
Reliability/Validity Robaey et al. J Canad ACAP 88 children (match to Conner’s Rating
Scale)
Genetic Hay et al. Biol Psych 528 participants (age 6–9); 488 (age 12–20)
Evaluate/Diagnose Lubke et al. J Amer ACAP Finland Cohort
Pharmacology Abikoff et al. JChAdolPsychph 114 preschoolers
Evaluate/Diagnose Polderman et al. JCPP 560 and 469
Evaluate/Diagnose Smalley et al. J Amer ACAP Finland Cohort
Pharmacology Vitiello et al J Child Adolesc
Psycopharmacol
95 children
2008 Genetic Cornish et al. Neuropsych 157 children (age 6–11)
Pharmacology So et al. BehavResTherap 90 children (age 7–10)
2009 Imaging Volkow et al. JAMA 53 ADHD and 44 controls
Reliability/Validity Young et al. ChPsyHumDev The Australian Twin ADHD Study
2010 Genetic Arcos-Burgos et al. Mol Psych Family-population based study
Reliability/Validity Lakatos et al. PsychHung 156 children (age 6)
2012 Neuropsychology Figueroa-Varela PhD Thesis 18 adolescents
Neuropsychology Serrien et al. Develop Psych 98 children (age 4–10)
Evaluate/Diagnose Normand et al. J Abnorm ChPsy 510 children (age 6–9)
Evaluate/Diagnose Kudo et al. IJEPA 1528 parents of preschoolers
2013 Neuropsychology Arnett et al. J Attent Dis 1502 children (age 5–8)
Neuropsychology Sims et al. JCCAP 204 children
Evaluate/Diagnose Crosbie et al. J Abnorm ChPsy 16,099 children (age 6–18)
Reliability/Validity Lai et al. J Attent Dis 3772 children (age 6–12)
SWAN: Strengths and Weaknesses of Attention-Deficit/Hyperactivity-symptoms and Normal-behaviors rating scale.
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the SWAN scale, So et al. (36) compared the effective-
ness of stimulant-only treatment with stimulant and
behavioral psychotherapy treatment of Chinese children
with ADHD associated with oppositional defiant disorder
(ODD). They revealed that although medication-only
treatment improved both ADHD and ODD symptoms, a
combination of medication and behavioral therapy was
more effective. The findings show that the pharmacolog-
ical approach resulted in a reduction in ODD symptoms
and an improvement in parental adherence to the
treatment (36).
Studies on neuropsychological aspects
of ADHD
Neuropsychological approaches are considered essen-
tial in constructing endophenotypic markers for ADHD.
Evidence shows that ADHD leads to deficits in executive
functions, selective and sustained attention, short-term
memory, self-regulation, and control inhibition (2,4,5). Three
articles used the SWAN scale as a comparative resource in
associating ADHD and its subtypes with deficiencies in
reading ability (37), working memory (38), response
inhibition (22), and visual performance (35). These studies
used the SWAN method to determine which ADHD
subtypes cause greater damage and in which specific
abilities ADHD causes greater functional restrictions.
Another study compared ADHD to disruptive behavior
and showed that it was possible to identify positive attention
and impulse regulation behaviors (20). Serrien et al. used
the SWAN for screening children between 4 and 10 years
of age and were able to identify which bimanual and
unimanual coordination abilities are negatively influenced
during childhood development if target symptoms of ADHD
are present (39). Figueroa-Varela (31) used SWAN self-
evaluations to assess average impulsiveness in adoles-
cents and found a positive correlation between impulsive-
ness and symptoms of ADHD.
Studies of statistical reliability and validity
Statistics (or the development of statistical interpreta-
tion) in neuropsychiatric disorders, or in studies of
complex traits and conditions like ADHD that show
gene–environment interactions, have permitted improve-
ments in the use of phenotypic information, allowing
comparison of allele frequency between cases and
controls and more power to detect statistically significant
gene sequences. The development of questionnaires and
referential scales, in turn, strengthens statistical power (17).
Seven articles from this review analyzed the statistical
reliability of the SWAN scale compared with other con-
solidated and validated scales; for example, SNAP-IV (16),
CBCL (25,26), and ADS-IV (9). All seven studies attested to
the reliability of SWAN. A study using both SWAN and
Conners’ Continuous Performance Test (CPT-II) ratings,
which is considered the gold standard in verifying ADHD (8),
showed a 0.80 correlation for parent interviews and a 0.90
correlation for teacher ratings (32). The same result was
found in an analysis of ADHD symptoms assessed by SWAN
using a Rasch model (40). Tests of SWAN’s statistical
stability by translating and validating it for other languages
and cultures have found that the French version of the
scale (23) has good internal consistency (Cronbach’s
alpha 48), validity, excellent stability (0.86), and specificity
(0.88). Similar results have been found in studies in other
countries, such as China (15), Hungary (41), Spain (28,42),
and Hong Kong (43).
Studies on ADHD and comorbidities
Only one study used the SWAN scale to correlate
ADHD and developmental coordination disorder scores
(44); this study demonstrated an overlap in the symptoms
of the two conditions, especially with inattentive subtypes.
Another study examined the differential diagnosis of
similar comorbidities for ADHD and ODD) and described
SWAN as a sensitive scale for detecting ADHD (9).
Studies on neuroimaging
One study (45) used SWAN to correlate negative or
positive attention variation with brain regions related to
signal intensity in the reward system (dopamine receptors
D2/D3). An inversely proportional relation was confirmed:
the smaller the intensity of the dopamine signal, the
greater the attentional deficit. In this and one other study
(38), items derived from SWAN allowed the evaluation of
correlations between behavior and functional cerebral
connections.
Results and Discussion
This article reviewed studies that applied the SWAN
scale to various fields, from statistical analysis to clinical
use in ADHD diagnostic and therapeutic processes. Its
use in evaluating phenotypic attentional characteristics
and their variations could help ADHD researchers to
correlate genetic measures with phenotypic ADHD traits.
The scale has also been useful in the quantitative
assessment of pharmacological treatment, the compar-
ison of results across a range of statistically consolidated
scales, and the correlation of ratings with neuropsycholog-
ical data.
Crosschecking data from the scale with allelic
repetitions in large population samples, active func-
tional standards of neuroimaging, and pharmaceutical
evolution (placebo vs medication) is valuable in gen-
erating new scientific research strategies in the ADHD
field, especially those that search for more biological
markers and those that aim to clarify physiopathological
mechanisms.
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However, there is still little research using SWAN to
define diagnostic evaluation of the disorder, as there are still
no strong cohort studies with accurate t-score and
z-score data to define characteristics of normal and
abnormal distributions; neither are there any standards
regarding age, gender, or maturity levels. There is also a
lack of definitive evidence on the scale’s contributions to
comorbidity research, neuroimaging, and genetics, because
of the limited number of articles available on these subjects.
Conclusions
There are several global challenges to ADHD diag-
nosis: its significant cultural heterogeneity, scarce reliable
scientific information on ADHD in the educational field and
on differences between countries (generating widespread
ignorance about the possible over-diagnosis of this
disorder), and the relative lack of specialists in most
countries to adequately evaluate children and adoles-
cents. The SWAN scale could contribute to the work of
professionals in tracking additional problems in childhood
and could improve both diagnostic work and studies on
the ADHD spectrum.
Acknowledgments
We are greatly indebted to Dr. James M. Swanson,
professor at University of California, Irvine, for helping with
articles used in this paper and for his research on
dimensional diagnostics in ADHD, and to Dr. Joseph A.
Sergeant, Emeritus Professor at Vrije Universiteit in
Amsterdam, for his reviews, discussions, and his lifelong
research into ADHD. We thank both professors for their
valuable suggestions and help with this paper.
References
1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA.
The worldwide prevalence of ADHD: a systematic review and
metaregression analysis. Am J Psychiatry 2007; 164: 942–948.
2. Scheres A, Oosterlaan J, Swanson J, Morein-Zamir S,
Meiran N, Schut H, et al. The effect of methylphenidate on
three forms of response inhibition in boys with AD/HD.
J Abnorm Child Psychol 2003; 31: 105–120, doi: 10.1023/
A:1021729501230.
3. Schmitz M, Polanczyk G, Rohde LA. ADHD: remission in
adolescence and predictors of persistence into adulthood.
J Bras Psiq 2007; 56 (Suppl 1): 25–29.
4. Coghill D, Soutullo C, d’Aubuisson C, Preuss U, Lindback T,
Silverberg M, et al. Impact of attention-deficit/hyperactivity
disorder on the patient and family: results from a European
survey. Child Adolesc Psychiatry Ment Health 2008; 2: 31,
doi: 10.1186/1753-2000-2-31.
5. Castellanos FX, Tannock R. Neuroscience of attention-deficit/
hyperactivity disorder: the search for endophenotypes. Nat
Rev Neurosci 2002; 3: 617–628, doi: 10.1038/nrn896.
6. Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ,
Radua J. Effects of stimulants on brain function in attention-
deficit/hyperactivity disorder: a systematic review and meta-
analysis. Biol Psychiatry 2014; 76: 616–628, doi: 10.1016/j.
biopsych.2013.10.016.
7. Martin J, Hamshere ML, Stergiakouli E, O’Donovan MC,
Thapar A. Genetic risk for attention-deficit/hyperactivity
disorder contributes to neurodevelopmental traits in the
general population. Biol Psychiatry 2014; 76: 664–671, doi:
10.1016/j.biopsych.2014.02.013.
8. Kollins SH, Sparrow EP, Conners CK. Guide to assessment
scales in ADHD. Nova York: Springer Healthcare. ISBN 978-
1- 907673-15-3; 2010.
9. Waschbusch DA, Sparkes S. Rating Scale Assessment of
ADHD and ODD: Is there a normal distribution and does it
matter? J Psychoeduc Assess 2003; 21: 261–281, doi:
10.1177/073428290302100303.
10. Benczik EBP, Schelini PW, Casella EB. Evaluation Instru-
ment of ADHD in adolescents and adults. Psychol Bull 2010;
131: 137–151.
11. Mattos P, Segenreich D, Saboya E, Louzã M, Dias G,
Romano M. Portuguese Transcultural Adoption for the Adult
Self-Report Scale (ASRS- 18, version 1.1) to evaluate
symptoms of Hyperactive Attention Deficit Disorder (ADHD)
in adults. Rev Bras Psiq 2006; 33: 188–194.
12. Mattos P, Rohde LA. Principles and practices in ADHD.
Porto Alegre: Ed. Artmed; 2008.
13. Eisenberg L, Landowne EJ, Wilner DM, Imber SD. The use
of teacher ratings in a mental health study: a method for
measuring the effectiveness of a therapeutic nursery
program. Am J Public Health Nations Health 1962; 52:
18–28, doi: 10.2105/AJPH.52.1.18.
14. Smalley SL, McGough JJ, Moilanen IK, Loo SK, Taanila A,
Ebeling H, et al. Prevalence and psychiatric comorbidity
of attention-deficit/hyperactivity disorder in an adolescent
Finnish population. J Am Acad Child Adolesc Psychiatry
2007; 46: 1575–1583, doi: 10.1097/chi.0b013e3181573137.
15. Lai KY, Leung PW, Luk ES, Wong AS, Law LS, Ho KK.
Validation of the Chinese strengths and weaknesses of
ADHD-symptoms and normal-behaviors questionnaire in
Hong Kong. J Atten Disord 2013; 17: 194–202, doi: 10.1177/
1087054711430711.
16. Swanson J, Schuck S, Mann M, Carlson C, Hartman K,
Sergeant JA, et al. Over- identification of extreme behavior
in evaluation and diagnosis of ADHD/HKD. www.adhd.net/
SWAN_Paper.pdf.
17. van der Sluis S, Posthuma D, Nivard MG, Verhage M,
Dolan CV. Power in GWAS: lifting the curse of the clinical
cut-off. Mol Psychiatry 2013; 18: 2–3, doi: 10.1038/mp.
2012.65.
18. Ramos-Quiroga JA, Sanchez-Mora C, Casas M, Garcia-
Martinez I, Bosch R, Nogueira M, et al. Genome-wide copy
number variation analysis in adult attention-deficit and
hyperactivity disorder. J Psychiatr Res 2014; 49: 60–67,
doi: 10.1016/j.jpsychires.2013.10.022.
19. Jacob CP, Weber H, Retz W, Kittel-Schneider S, Heupel J,
Renner T, et al. Acetylcholine-metabolizing butyrylcholines-
terase (BCHE) copy number and single nucleotide poly-
morphisms and their role in attention-deficit/hyperactivity
www.bjournal.com.br Braz J Med Biol Res 48(11) 2015
SWAN and ADHD 971
syndrome. J Psychiatr Res 2013; 47: 1902–1908, doi:
10.1016/j.jpsychires.2013.08.006.
20. Arnett AB, Pennington BF, Friend A, Willcutt EG, Byrne B,
Samuelsson S, et al. The SWAN captures variance at the
negative and positive ends of the ADHD symptom dimen-
sion. J Atten Disord 2013; 17: 152–162, doi: 10.1177/
1087054711427399.
21. Swanson JM, Wigal T, Lakes K. DSM-V and the future
diagnosis of attention-deficit/hyperactivity disorder. Curr
Psychiatry Rep 2009; 11: 399–406, doi: 10.1007/s11920-
009-0060-7.
22. Crosbie J, Arnold P, Paterson A, Swanson J, Dupuis A, Li X,
et al. Response inhibition and ADHD traits: correlates and
heritability in a community sample. J Abnorm Child Psychol
2013; 41: 497–507, doi: 10.1007/s10802-012-9693-9.
23. Robaey P, Amre D, Schachar R, Simard L. French version of
the strengths and weaknesses of ADHD symptoms and
normal behaviors (SWAN-F) questionnaire. J Can Acad
Child Adolesc Psychiatry 2007; 16: 80–89.
24. Brock S, Jimerson SR, Hansen RL. Identifying, assessing
and treating ADHD at School. New York: Ed. Springer; 2009.
25. Polderman TJ, Derks EM, Hudziak JJ, Verhulst FC,
Posthuma D, Boomsma DI. Across the continuum of
attention skills: a twin study of the SWAN ADHD rating
scale. J Child Psychol Psychiatry 2007; 48: 1080–1087, doi:
10.1111/j.1469-7610.2007.01783.x.
26. Abikoff HB, Vitiello B, Riddle MA, Cunningham C, Greenhill
LL, Swanson JM, et al. Methylphenidate effects on
functional outcomes in the Preschoolers with Attention-
Deficit/Hyperactivity Disorder Treatment Study (PATS).
J Child Adolesc Psychopharmacol 2007; 17: 581–592, doi:
10.1089/cap.2007.0068.
27. Hay DA, Bennett KS, Levy F, Sergeant J, Swanson J.
A twin study of attention-deficit/hyperactivity disorder
dimensions rated by the strengths and weaknesses of
ADHD-symptoms and normal-behavior (SWAN) scale. Biol
Psychiatry 2007; 61: 700–705, doi: 10.1016/j.biopsych.
2006.04.040.
28. Kudo M, Altamirano W, Mearns J. SWAN Preschool Rating
Scale (SWAN-P): Validity Evidence for English and Spanish
Versions. Int J Educ Psychol Assess 2012; 10: 139–157.
29. Lubke GH, Muthen B, Moilanen IK, McGough JJ, Loo SK,
Swanson JM, et al. Subtypes versus severity differences in
attention-deficit/hyperactivity disorder in the Northern Fin-
nish Birth Cohort. J Am Acad Child Adolesc Psychiatry
2007; 46: 1584–1593, doi: 10.1097/chi.0b013e31815750dd.
30. Normand S, Flora DB, Toplak ME, Tannock R. Evidence
for a general ADHD factor from a longitudinal general
school population study. J Abnorm Child Psychol 2012; 40:
555–567, doi: 10.1007/s10802-011-9584-5.
31. Figueroa-Varela M. Behavioral and Impulsivity psychophy-
siological evaluation and its relationship with Attention deficit
hyperactivity disorder (ADHD). [Doctoral Thesis]. Granada:
Granada University; 2012.
32. Cornish KM, Manly T, Savage R, Swanson J, Morisano D,
Butler N, et al. Association of the dopamine transporter
(DAT1) 10/10-repeat genotype with ADHD symptoms and
response inhibition in a general population sample. Mol
Psychiatry 2005; 10: 686–698, doi: 10.1038/sj.mp.4001641.
33. Arcos-Burgos M, Jain M, Acosta MT, Shively S, Stanescu H,
Wallis D, et al. A common variant of the latrophilin 3 gene,
LPHN3, confers susceptibility to ADHD and predicts
effectiveness of stimulant medication. Mol Psychiatry
2010; 15: 1053–1066, doi: 10.1038/mp.2010.6.
34. Cornish KM, Wilding JM, Hollis C. Visual search perfor-
mance in children rated as good or poor attenders: the
differential impact of DAT1 genotype, IQ, and chronological
age. Neuropsychology 2008; 22: 217–225, doi: 10.1037/
0894-4105.22.2.217.
35. Vitiello B, Abikoff HB, Chuang SZ, Kollins SH, McCracken
JT, Riddle MA, et al. Effectiveness of methylphenidate in
the 10-month continuation phase of the Preschoolers with
Attention-Deficit/Hyperactivity Disorder Treatment Study
(PATS). J Child Adolesc Psychopharmacol 2007; 17:
593–604, doi: 10.1089/cap.2007.0058.
36. So CYC, Leung PWL, Hung SF. Treatment effectiveness of
combined medication/behavioural treatment with Chinese
ADHD children in routine practice. Behav Res Ther 2008;
46: 983–992, doi: 10.1016/j.brat.2008.06.007.
37. Sims DM, Lonigan CJ. Inattention, hyperactivity, and
emergent literacy: different facets of inattention relate
uniquely to preschoolers’ reading-related skills. J Clin Child
Adolesc Psychol 2013; 42: 208–219, doi: 10.1080/
15374416.2012.738453.
38. Lui M, Tannock R. Working memory and inattentive
behaviour in a community sample of children. Behav Brain
Funct 2007; 3: 12, doi: 10.1186/1744-9081-3-12.
39. Serrien DJ, Sovijarvi-Spape MM, Rana G. Developmental
changes in motor control: insights from bimanual coordination.
Dev Psychol 2014; 50: 316–323, doi: 10.1037/a0032996.
40. Young DJ, Levy F, Martin NC, Hay DA. Attention deficit
hyperactivity disorder: a Rasch analysis of the SWAN Rating
Scale. Child Psychiatry Hum Dev 2009; 40: 543–559, doi:
10.1007/s10578-009-0143-z.
41. Lakatos K, Birkas E, Toth I, Gervai J. [Screening childhood
behavior problems using short questionnaires II.: The
Hungarian version of the SWAN-scale (Strength and
Weakness of ADHD-symptoms and Normal-behavior) for
screening attention deficit/hyperactivity disorder]. Psychiatr
Hung 2010; 25: 493–502.
42. Lakes KD, Swanson JM, Riggs M. The reliability and validity
of the English and Spanish Strengths and Weaknesses of
ADHD and Normal behavior rating scales in a preschool
sample: continuum measures of hyperactivity and inatten-
tion. J Atten Disord 2012; 16: 510–516, doi: 10.1177/
1087054711413550.
43. Leung PW, Hung SF, Ho TP, Lee CC, Liu WS, Tang CP, et al.
Prevalence of DSM-IV disorders in Chinese adolescents
and the effects of an impairment criterion: a pilot community
study in Hong Kong. Eur Child Adolesc Psychiatry 2008; 17:
452–461, doi: 10.1007/s00787-008-0687-7.
44. Martin NC, Piek JP, Hay D. DCD and ADHD: a genetic study
of their shared aetiology. Hum Mov Sci 2006; 25: 110–124,
doi: 10.1016/j.humov.2005.10.006.
45. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH,
Telang F, et al. Evaluating dopamine reward pathway in
ADHD: clinical implications. JAMA 2009; 302: 1084–1091,
doi: 10.1001/jama.2009.1308.
Braz J Med Biol Res 48(11) 2015 www.bjournal.com.br
972 C. Brites et al.
